CDKN2A and neoplasm: Only 50% of cases with homozygous CDKN2A deletions (14/28) had complete loss of p16 immunoreactivity (“0” score), while 28% (A/B) had minimal staining (“+1” score, 0–9% positive tumor cells, Fig. 5k).